Number of drugs (fifth ATC level) by class with enough exposure to study the given incidences with the given relative risks (RRs)
| ≤1/100 000 PYs | ≤10/100 000 PYs | ≤50/100 000 PYs | ≤100/100 000 PYs | ≤500/100 000 PYs | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First ATC tclass * | RR ≥2 | RR ≥4 | RR ≥6 | RR ≥2 | RR ≥4 | RR ≥6 | RR ≥2 | RR ≥4 | RR ≥6 | RR ≥2 | RR ≥4 | RR ≥6 | RR ≥2 | RR ≥4 | RR ≥6 | |
| Alimentary (n = 391) | N (%) | - | - | - | - | 1 (0.3) | 2 (0.5) | 1 (0.3) | 11 (2.8) | 21 (5.4) | 2 (0.5) | 20 (5.1) | 37 (9.5) | 14 (3.6) | 52 (13.3) | 66 (16.9) |
| Respiratory (n = 160) | N (%) | - | - | 3 (1.9) | 2 (1.3) | 15 (9.4) | 21 (13.1) | 12 (7.5) | 29 (18.1) | 37 (23.1) | 18 (11.3) | 35 (21.9) | 47 (29.4) | 30 (18.8) | 54 (33.8) | 63 (39.4) |
| Dermatological (n = 203) | N (%) | - | - | - | - | 2 (1.0) | 8 (3.9) | 1 (0.5) | 14 (6.9) | 23 (11.3) | 5 (2.5) | 23 (11.3) | 35 (17.2) | 19 (9.4) | 48 (23.6) | 62 (30.5) |
| Anti-infectives (n = 232) | N (%) | - | - | 2 (0.9) | 1 (0.4) | 5 (2.2) | 8 (3.4) | 3 (1.3) | 12 (5.2) | 22 (9.5) | 6 (2.6) | 19 (8.2) | 28 (12.1) | 17 (7.3) | 40 (17.2) | 58 (25.0) |
| Neurologic (n = 269) | N (%) | - | - | - | - | 2 (0.7) | 2 (0.7) | 1 (0.4) | 9 (3.3) | 19 (7.1) | 2 (0.7) | 19 (7.1) | 27 (10.0) | 14 (5.2) | 41 (15.2) | 57 (21.2) |
| Sensory organs (n = 169) | N (%) | - | - | - | - | - | 1 (0.6) | - | 5 (3.0) | 12 (7.1) | - | 12 (7.1) | 19 (11.2) | 11 (6.5) | 34 (20.1) | 42 (24.9) |
| Cardiovascular (n = 192) | N (%) | - | - | - | - | - | - | - | - | 5 (2.6) | - | 3 (1.6) | 9 (4.7) | - | 18 (9.4) | 33 (17.2) |
| Genitourinary (n = 153) | N (%) | - | - | 1 (0.7) | - | 2 (1.3) | 4 (2.6) | 2 (1.3) | 5 (3.3) | 8 (5.2) | 3 (2.0) | 8 (5.2) | 11 (7.2) | 8 (5.2) | 24 (15.7) | 32 (20.9) |
| Hormones (n = 72) | N (%) | - | - | - | - | 2 (2.8) | 8 (11.1) | - | 10 (13.9) | 14 (19.4) | 4 (5.6) | 14 (19.4) | 18 (25.0) | 14 (19.4) | 24 (33.3) | 30 (41.7) |
| Musculoskeletal (n = 104) | N (%) | - | - | - | - | - | - | - | 2 (1.9) | 5 (4.8) | - | 4 (3.8) | 7 (6.7) | 3 (2.9) | 8 (7.7) | 18 (17.3) |
| Blood (n = 97) | N (%) | - | - | - | - | - | 2 (2.1) | - | 3 (3.1) | 6 (6.2) | 2 (2.1) | 5 (5.2) | 7 (7.2) | 3 (3.1) | 11 (11.3) | 16 (16.5) |
| Antiparasitic (n = 35) | N (%) | - | - | - | - | - | - | - | - | 1 (2.9) | - | 1 (2.9) | 1 (2.9) | - | 5 (14.3) | 11 (31.4) |
| Antineoplastics (n = 76 | N (%) | - | - | - | - | - | - | - | - | 2 (2.6) | - | 2 (2.6) | 5 (6.6) | - | 6 (7.9) | 10 (13.2) |
| Total (n = 2170) | N (%) | - | - | 6 (0.3) | 3 (0.1) | 29 (1.3) | 56 (2.6) | 20 (0.9) | 100 (4.6) | 175 (8.1) | 42 (1.9) | 165 (7.6) | 251 (11.6) | 133 (6.1) | 365 (16.8) | 498 (22.9) |
*
First ATC level ‘Various’ (n = 35) had no drugs with enough exposure for any of the incidences and is not presented.